NeuBase Therapeutics (NasdaqCM:NBSE) - Share price, News & Analysis

NBSE fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

NBSE Stock Overview

NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes.

Risk Analysis

Earnings are forecast to decline by an average of 14.4% per year for the next 3 years

Makes less than USD$1m in revenue ($0)

Currently unprofitable and not forecast to become profitable over the next 3 years

Does not have a meaningful market cap ($32M)

NeuBase Therapeutics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for NeuBase Therapeutics
Historical stock prices
Current Share Price	US$1.00
52 Week High	US$5.51
52 Week Low	US$0.89
Beta	0.77
1 Month Change	-30.56%
3 Month Change	-24.81%
1 Year Change	-80.81%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-78.02%

Recent News & Updates

May 12

We Think NeuBase Therapeutics (NASDAQ:NBSE) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Shareholder Returns

	NBSE	US Biotechs	US Market
7D	5.0%	1.4%	-2.7%
1Y	-80.8%	-21.7%	-12.9%

Return vs Industry: NBSE underperformed the US Biotechs industry which returned -22.1% over the past year.

Return vs Market: NBSE underperformed the US Market which returned -12.7% over the past year.

Price Volatility

Is NBSE's price volatile compared to industry and market?
NBSE volatility
NBSE Average Weekly Movement	12.0%
Biotechs Industry Average Movement	12.4%
Market Average Movement	7.9%
10% most volatile stocks in US Market	16.9%
10% least volatile stocks in US Market	3.0%

Stable Share Price: NBSE is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: NBSE's weekly volatility (12%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
n/a	33	Dietrich Stephan	https://www.neubasetherapeutics.com

NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company’s proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington’s disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington’s disease; NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1; NT0300, a PATrOL-enabled therapeutic treatment to target the mutated KRAS gene.

NeuBase Therapeutics Fundamentals Summary

How do NeuBase Therapeutics's earnings and revenue compare to its market cap?
NBSE fundamental statistics
Market Cap	US$32.26m
Earnings (TTM)	-US$33.47m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-1.0x

P/E Ratio

Is NBSE overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
NBSE income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$33.47m
Earnings	-US$33.47m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-1.04
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did NBSE perform over the long term?

See historical performance and comparison

Valuation

Is NeuBase Therapeutics undervalued compared to its fair value and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

0.85x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate NBSE's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate NBSE's fair value for valuation analysis.

Price To Earnings Ratio

PE vs Industry: NBSE is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: NBSE is unprofitable, so we can't compare its PE Ratio to the US market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate NBSE's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: NBSE is good value based on its PB Ratio (0.8x) compared to the US Biotechs industry average (1.5x).

Future Growth

How is NeuBase Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

-14.4%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: NBSE is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: NBSE is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: NBSE is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: NBSE is forecast to have no revenue next year.

High Growth Revenue: NBSE is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if NBSE's Return on Equity is forecast to be high in 3 years time

Past Performance

How has NeuBase Therapeutics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-18.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: NBSE is currently unprofitable.

Growing Profit Margin: NBSE is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: NBSE is unprofitable, and losses have increased over the past 5 years at a rate of 18.9% per year.

Accelerating Growth: Unable to compare NBSE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NBSE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).

Return on Equity

High ROE: NBSE has a negative Return on Equity (-87.71%), as it is currently unprofitable.

Financial Health

How is NeuBase Therapeutics's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: NBSE's short term assets ($40.2M) exceed its short term liabilities ($5.0M).

Long Term Liabilities: NBSE's short term assets ($40.2M) exceed its long term liabilities ($5.7M).

Debt to Equity History and Analysis

Debt Level: NBSE is debt free.

Reducing Debt: NBSE had no debt 5 years ago.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NBSE has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: NBSE has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 60% each year.

Dividend

What is NeuBase Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate NBSE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NBSE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NBSE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NBSE's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as NBSE has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.2yrs

Average management tenure

CEO

Dietrich Stephan (51 yo)

2.83yrs

Tenure

US$1,513,718

Compensation

Dr. Dietrich A. Stephan, Ph D., is the Founder of Silicon Valley Biosystems, Inc., and serves as its Chief Executive Officer and President. Dr. Stephan serves as Scientist in Chief and Founding Member at L...

CEO Compensation Analysis

Compensation vs Market: Dietrich's total compensation ($USD1.51M) is above average for companies of similar size in the US market ($USD771.97K).

Compensation vs Earnings: Dietrich's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: NBSE's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.

Board Members

Experienced Board: NBSE's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: NBSE insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/05/21 00:00
End of Day Share Price	2022/05/20 00:00
Earnings	2022/03/31
Annual Earnings	2021/09/30